Protego Biopharma
SAN DIEGO, CA · Biotechnology · 26 employees
Protego Bio is a clinical-stage company focused on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our appro
Funding history
- Funding Round — $32.9M — Dec 2025
- Series series b — $130.0M — Dec 2025
- Funding Round — $51.0M — Oct 2021
- Funding Round — $1.0M — Dec 2019
Recent signals
- Jun 08, 2026: Protego Biopharma Appoints Jae B. Kim as Chief Medical Officer
- Dec 03, 2025: Raised $32.9M
- Dec 01, 2025: Raised $130.0M in Series series b
- Oct 28, 2021: Raised $51.0M
- Dec 17, 2019: Raised $1.0M
See plans & pricing → Track Protego Biopharma’s funding, hiring, and signals — with verified contacts — on Fundz.